Clarity Pharmaceuticals Limited (ASX:CU6): Prostate Cancer Imaging and Therapy Trials

Aditi Sarkar

30 October 2026 08:16 PM AEDT

Clarity Pharmaceuticals Limited (ASX:CU6): Prostate Cancer Imaging and Therapy Trials

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Clarity develops radiopharmaceutical candidates for cancer imaging and treatment.
The Phase III CLARIFY study reached its target enrolment in October 2026.
The SECuRE trial also reported a recruitment milestone during October.
The company’s SAR-bisPSMA programme includes diagnostic and therapeutic applications.
Trial recruitment milestones differ from efficacy results and regulatory decisions.

Clarity Pharmaceuticals Limited is a clinical-stage radiopharmaceutical company developing products for cancer imaging and treatment. Its current clinical programme includes prostate cancer studies using copper-based radiopharmaceutical technology. The company announced separate recruitment milestones for the CLARIFY and SECuRE studies in October 2026, documenting progress in two programmes with different objectives.

CLARIFY enrolment milestone

On 27 October 2026, Clarity Pharmaceuticals Limited (ASX:CU6) announced that the registrational Phase III CLARIFY trial had dosed its planned target of 383 participants. CLARIFY is part of the company's prostate cancer imaging programme. The number describes participants dosed in the study; it is not a count of successful scans, a measure of clinical effectiveness or a regulatory approval.

A registrational study aims to gather evidence relevant to a potential regulatory submission. It still requires appropriate analysis of study results and regulatory review. Clarity Pharmaceuticals Limited (ASX:CU6) has described recruitment and dosing progress, while the clinical significance of the resulting dataset depends on the study's specified endpoints and subsequent reporting.

SECuRE therapeutic development

The company reported on 8 October 2026 that recruitment had reached its target in the cohort-expansion main group of its Phase I/IIa SECuRE study. This programme evaluates a therapeutic approach using copper-67 SAR-bisPSMA. Clarity Pharmaceuticals Limited (ASX:CU6) had also released an August 2026 update on its 8 GBq dose level, describing two additional complete responses at that level.

The SECuRE development programme has different clinical objectives from CLARIFY imaging research. Clarity Pharmaceuticals Limited (ASX:CU6) must assess treatment-related outcomes and safety within the study design. Results from one cohort cannot automatically establish an outcome for all participants or support an assumption about a later regulatory decision.

Broader product platform

The company's pipeline includes SAR-bisPSMA, SARTATE and SAR-Bombesin programmes across cancer-related applications. Clarity Pharmaceuticals Limited (ASX:CU6) describes SAR-bisPSMA as being investigated for both diagnosis and therapy in prostate cancer. It also identifies SARTATE in neuroendocrine tumour imaging and SAR-Bombesin in prostate cancer imaging research.

Radiopharmaceutical products pair a targeting molecule with a radioactive isotope to support imaging or deliver radiation. Their development requires careful attention to clinical evidence, manufacturing, isotope supply and regulatory standards. The pipeline therefore covers several different technical and clinical settings rather than a single interchangeable product.

Clinical and operational considerations

Clinical-stage companies incur trial and manufacturing expenses before receiving product approval. Study recruitment is a concrete operational achievement, but patient outcomes, safety findings and the results of formal analyses remain separate matters. Clarity Pharmaceuticals Limited (ASX:CU6) has scheduled its annual general meeting for 25 November 2026, providing another formal company reporting event.

Key Insights

The CLARIFY and SECuRE studies also illustrate how different uses of a radiopharmaceutical require different kinds of clinical evidence. Imaging research assesses diagnostic performance, whereas therapeutic studies address patient outcomes and tolerability. Clinical protocols, follow-up periods and data analyses determine the context in which reported findings can be interpreted. These differences are central to Clarity Pharmaceuticals Limited (ASX:CU6) and its development programme. Clarity’s October 2026 announcements establish recruitment and dosing progress across distinct prostate cancer studies. CLARIFY concerns imaging, while SECuRE investigates treatment. The company’s broader platform also encompasses other radiopharmaceutical candidates, all subject to the evidence and approvals relevant to their individual intended uses.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.